The exposure of patients to the plasticizer di-(2-ethylhexyl)phthalate (DEHP) from polyvinyl chloride (PVC) tubes and bags during dialysis has been investigated. In vitro studies of the migration of DEHP from hemodialysis tubes into plasma revealed a migration coefficient of 7.7 μg/ml/h. An artificial kidney did not influence the plasma concentration of DEHP. The calculated exposure from a single hemodialysis can be as much as the total annual exposure using continuous ambulatory peritoneal dialysis (CAPD). CAPD fluids in PVC bags contain low concentrations of DEHP and its hydrolysis product mono-(2-ethylhexyl)phthalate (MEHP). These phthalates were analyzed in serum from patients receiving both CAPD and hemodialysis using gas chromatography. A group of patients not yet on dialysis treatment was used as control. In no case could MEHP be detected. The DEHP concentration was 0.8–4.2 μg/ml serum in the 17 hemodialysis patients after dialysis and 0.1–0.9 μg/ml in 4 of the CAPD patients. In 3 of the CAPD and all of the predialysis patients, DEHP could not be detected ( < 0.1 μg/ml).

Keywords:
Hemodialysis, Continuous ambulatory peritoneal dialysis, Polyvinyl chloride, Di-(2-ethylhexyl)phthalate
This content is only available via PDF.
© 1987 S. Karger AG, Basel
1987
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.